immunoSEQ Assays illuminate the adaptive immune system with bias-controlled multiplex PCR amplification and high-throughput sequencing of T- and B-cell receptors, combined with sophisticated bioinformatics. The immunoSEQ Platform’s core technology provides the foundation for all research products at Adaptive Biotechnologies.
The immunoSEQ Assay is available in two forms:
as a sequencing service performed in Adaptive’s lab, and as a Research Use Only Kit that offers the convenience and control of sequencing in the lab of your choice. With both options, sequence data is converted by the immunoSEQ Analyzer into a quantitative profile available in the cloud.
Integrate highly optimized multiplex PCR with high-throughput
sequencing and advanced bioinformatics to track clones,
profile immune repertoires, and identify public clones.
For Drug Development
Incorporate the immunoSEQ Assay into clinical trials to monitor
response to drugs in development and discover new prognostic
and diagnostic biomarkers.
CONTROL FOR PCR AMPLIFICATION BIAS
Employing highly optimized PCR primers and a synthetic immune repertoire with computational algorithms, the immunoSEQ Assay delivers accurate, quantifiable results.
Primer concentrations adjusted to significantly reduce PCR amplification bias
Built-in controls assessed with every sample for true quantification
Corrects residual PCR amplification bias and quantifies T-cell or B-cell clones
Carlson C.S. et al. Using Synthetic templates to design unbiased multiplex PCR assay. Nat. Commun. 2013:42680
SEMINARS & CONFERENCES
Join us for an upcoming seminar or at a conference exhibit for an in depth technical review of our products, an overview of important applications and to learn about new products.
NRG ONCOLOGY JULY 2015 MEETING
July 17, 2015
Sheraton Denver Downtown
11:00 am – 12:30 pm
Immune Therapy and Immune Modulation Workshop:
Trial Design Focus: T-cell Clonality to Predict Patient Responses to Immunotherapy:
Company Perspective - Immunosequencing: Unveiling New Molecular Biomarkers for Immunotherapy.
Presenter: Catherine Sanders, PhD, Adaptive Biotechnologies
4:00 pm – 6:00 pm
Translational Science Lung Cancer Subcommittee:
Immunosequencing: Generating a Potential New Class of Diagnostics
Presenter: Sharon Benzeno, PhD, MBA, Adaptive Biotechnologies
Click here for more information.
READY TO MOVE FORWARD? TALK TO US.
Learn how immunoSEQ Assays can advance your research.
CALL US AT 855-466-8667
For Research Use Only. Not for use in diagnostic procedures.